In zahlreichen Studien wird Frau Dr. Susan Feyerabend, Studienpraxis Urologie, Nuertingen als Top-Recruiter zur Ko-Autorin in die Publikation berufen.

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-Analysis.

Susan Feyerabend, Fred Saad, Tracy Li, Tetsuro Ito, Joris Diels, Suzy Van Sanden, Peter De Porre, Julie Roiz, Seye Abogunrin, Maria Koufopoulou, Karim Fizazi

European Journal of Cancer 103 (2018) 78e87

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators (:..Feyerabend S).

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

PMID: 29420164

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

Rausch S, Gouttefangeas C, Hennenlotter J, Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja H, Frick A, Kröger N, Stevanović S, Stenzl A, Rammensee HG, Bedke J.

Eur Urol Focus. 2017 Oct 4. pii: S2405-4569(17)30213-4. doi: 10.1016/j.euf.2017.09.009. [Epub ahead of print]

PMID: 28988765

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.

De Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, Baron B, Hirmand M, Werbrouck P, Fizazi K.

Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664-4. doi: 10.1016/j.eururo.2017.07.035. [Epub ahead of print]

PMID: 28844372

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators.

N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1704174. [Epub ahead of print]

PMID: 28578607

Custirsen in combination with doce and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS.

Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8.

PMID: 28283282

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597.

PMID: 27400947

Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Fahmy O, Scharpf M, Schubert T, Feyerabend S, Stenzl A, Schwentner C, Fend F, Gakis G.

Urol Int. 2016;97(4):485-488.

PMID: 26863306

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).

Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M.

BJU Int. 2014 Mar;113(3):429-36. doi: 10.1111/bju.12437.

PMID: 24053564

Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

Todenhöfer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, Kühs U, Gerber V, Fetisch J, Schilling D, Hauch S, Stenzl A, Schwentner C.

Anticancer Res. 2012 Aug;32(8):3507-13.

PMID: 22843938

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.

Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG.

Int J Cancer. 2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365.

PMID: 21858810

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA, de La Taille A.

BJU Int. 2010 Oct;106(8):1143-7. doi: 10.1111/j.1464-410X.2010.09286.x.

PMID: 20230386

Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.

Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C.

Cancer Res. 2009 Nov 1;69(21):8412-9. doi: 10.1158/0008-5472.CAN-09-0852.

PMID: 19843860

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A.

Prostate. 2009 Jun 15;69(9):917-27. doi: 10.1002/pros.20941.

PMID: 19267352

Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection.

Schostak M, Schwall GP, Poznanović S, Groebe K, Müller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, Schrattenholz A.

J Urol. 2009 Jan;181(1):343-53. doi: 10.1016/j.juro.2008.08.119.

PMID: 19012935

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA.

Eur Urol. 2008 Nov;54(5):1081-8. doi: 10.1016/j.eururo.2008.06.071.

PMID: 18602209

Cytotoxic effects of treosulfan on prostate cancer cell lines.

Feyerabend S, Feil G, Krug J, Kassen A, Stenzl A.

Anticancer Res. 2007 Jul-Aug;27(4B):2403-8. Erratum in: Anticancer Res. 2007 Sep-Oct;27(5b):3667.

PMID: 17695531

Doce, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.

Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D, Corvin S, Merseburger AS, Stenzl A.

Anticancer Res. 2005 Nov-Dec;25(6C):4481-6.

PMID: 16334130

Quelle: https://www.ncbi.nlm.nih.gov/pubmed/?term=susan+feyerabend